NCT06749236View on ClinicalTrials.gov

A Study to Evaluate the Bioavailability of Two Specifications of Oral Deuremidevir Hydrobromide for Suspension

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

August 1, 2025

Primary Completion Date

October 15, 2025

Study Completion Date

October 15, 2025

Conditions
Healthy Participants
Interventions
DRUG

test formulation(T) 200 mg deuteriumremidvir hydrobromide for suspension

Participants will receive a single dose of the test formulation(T) (one bag of 200 mg deuteriumremidvir hydrobromide for suspension).

DRUG

reference formulation(R) 100 mg deuteriumremidvir hydrobromide for suspension

Participants will receive a single dose of the reference formulation(R) ( two bags of 100 mg deuteriumremidvir hydrobromide for suspension).

Trial Locations (1)

233004

The First Affiliated Hospital of Bengbu Medical College, Xuzhou

All Listed Sponsors
lead

Vigonvita Life Sciences

INDUSTRY